Skip to main content

Table 1 Patient and tumor characteristics

From: The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer

Factor

 

Set 1

Set 2

Set 3

Set 4

Set 5

Total

No of patients

169

488

167

291

407

1,522

Events

20

55

39

39

82

235

Patient material I a

30

9

66

39

77

221

Patient material II a

0

0

0

67

99

166

Patient material III a

28

100

5

27

57

217

Patient material IV a

16

109

9

145

100

379

Patient material V a

95

270

87

13

74

539

Age median, years

45

65

53

61

61

60

Age range, years

28-50

50-90

27-93

30-88

33-89

27-93

Tumor size

      
 

≤ 20 mm

113 (67)b

364 (75)

68 (41)

115 (40)

208 (51)

868 (57)

 

>20 mm

56 (33)

124 (25)

99 (59)

176 (60)

199 (49)

654 (43)

Lymph nodes

      
 

Negative

169

488

0

291

0

948 (62)

1-3 positive

0

0

167

0

407

574 (38)

ER status

      
 

Positive

131 (78)

399 (82)

122 (73)

235 (81)

329 (81)

1,216 (80)

 

Negative

38 (22)

89 (18)

45 (27)

56 (19)

78 (19)

306 (20)

PgR status

      
 

Positive

46 (71)

121 (61)

56 (70)

168 (63)

200 (63)

591 (64)

 

Negative

19 (29)

76 (39)

24 (30)

100 (37)

118 (37)

337 (36)

 

Missing

104

291

87

23

89

594

Histological grade

      
 

1

41 (24)

136 (28)

19 (11)

32 (11)

67 (17)

295 (20)

 

2

82 (49)

250 (51)

97 (58)

166 (57)

233 (57)

828 (54)

 

3

46 (27)

102 (21)

51 (31)

93 (32)

107 (26)

399 (26)

Ki67

      
 

Low

109 (64)

343 (70)

111 (66)

210 (72)

315 (77)

1,088 (71)

 

Highc

60 (36)

145 (30)

56 (34)

81 (28)

92 (23)

434 (29)

HER2 status

      
 

Negative

54 (92)

142 (87)

62 (84)

216 (86)

249 (88)

723 (87)

 

Positived

5 (8)

21 (13)

12 (16)

36 (14)

33 (12)

107 (13)

 

Missing

110

325

93

39

125

692

Adjuvant endocrine treatment

      
 

Yes

0

0

0

291

407

698 (46)

 

No

169

488

167

0

0

824 (54)

  1. Patient materials I-V were pooled in a database from which the following subsets were extracted: Set 1: node-negative (N0), no adjuvant therapy, ≤50 years at diagnosis, Set 2: N0, no adjuvant therapy, >50 years at diagnosis, Set 3: node-positive (N1), no adjuvant therapy, Set 4: N0, adjuvant endocrine therapy, and Set 5: N1, adjuvant endocrine therapy.
  2. ER = estrogen receptor, PgR = progesterone receptor, HER2 = human epidermal growth factor 2.
  3. aPatient material I (Rydén et al. 2005), Patient material II (Swedish Breast Cancer Cooperative Group 1996; Chebil et al. 2003), Patient material III (Borgquist et al. 2008), Patient material IV (Falck et al. 2012), and Patient material V (Hansen et al. 2000).
  4. bNumbers in parentheses are percentages.
  5. cHigh Ki67 was previously defined as cases above the seventh decile in the empirical Ki67 distribution (which corresponds to 20% positive cells) (Klintman et al. 2010) and 20% was used for Patient materials I-IV. Cases above the median were considered Ki67 high in Patient material V.
  6. dHER2: positive if HER2-IHC 3+ or HER2-IHC 2+ and FISH amplified.